JP2015064362A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015064362A5 JP2015064362A5 JP2014218116A JP2014218116A JP2015064362A5 JP 2015064362 A5 JP2015064362 A5 JP 2015064362A5 JP 2014218116 A JP2014218116 A JP 2014218116A JP 2014218116 A JP2014218116 A JP 2014218116A JP 2015064362 A5 JP2015064362 A5 JP 2015064362A5
- Authority
- JP
- Japan
- Prior art keywords
- acid
- level
- sample
- lpc
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 25
- 239000000090 biomarker Substances 0.000 claims 21
- 239000000523 sample Substances 0.000 claims 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 11
- 239000008103 glucose Substances 0.000 claims 11
- 208000002705 Glucose Intolerance Diseases 0.000 claims 10
- 201000009104 prediabetes syndrome Diseases 0.000 claims 10
- 206010022489 Insulin Resistance Diseases 0.000 claims 9
- WWNNZCOKKKDOPX-UHFFFAOYSA-N N-methylnicotinate Chemical compound C[N+]1=CC=CC(C([O-])=O)=C1 WWNNZCOKKKDOPX-UHFFFAOYSA-N 0.000 claims 9
- 239000012472 biological sample Substances 0.000 claims 9
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 9
- 239000008777 Glycerylphosphorylcholine Substances 0.000 claims 8
- SUHOQUVVVLNYQR-MRVPVSSYSA-N choline alfoscerate Chemical compound C[N+](C)(C)CCOP([O-])(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-N 0.000 claims 8
- 229960004956 glycerylphosphorylcholine Drugs 0.000 claims 8
- 206010012601 diabetes mellitus Diseases 0.000 claims 7
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims 6
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 claims 6
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 claims 6
- BKAJNAXTPSGJCU-UHFFFAOYSA-N 4-methyl-2-oxopentanoic acid Chemical compound CC(C)CC(=O)C(O)=O BKAJNAXTPSGJCU-UHFFFAOYSA-N 0.000 claims 6
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 6
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims 6
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 5
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 5
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 5
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 5
- 239000005642 Oleic acid Substances 0.000 claims 5
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 5
- AFENDNXGAFYKQO-VKHMYHEASA-N (S)-2-hydroxybutyric acid Chemical compound CC[C@H](O)C(O)=O AFENDNXGAFYKQO-VKHMYHEASA-N 0.000 claims 4
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 claims 4
- 235000021355 Stearic acid Nutrition 0.000 claims 4
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims 4
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims 4
- 229960004488 linolenic acid Drugs 0.000 claims 4
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims 4
- 125000005645 linoleyl group Chemical group 0.000 claims 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 4
- 239000008117 stearic acid Substances 0.000 claims 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 3
- FPRKGXIOSIUDSE-SYACGTDESA-N (2z,4z,6z,8z)-docosa-2,4,6,8-tetraenoic acid Chemical compound CCCCCCCCCCCCC\C=C/C=C\C=C/C=C\C(O)=O FPRKGXIOSIUDSE-SYACGTDESA-N 0.000 claims 3
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims 3
- MVJLYXCJBPXRCY-UHFFFAOYSA-N 2-methylbutyl propanoate Chemical compound CCC(C)COC(=O)CC MVJLYXCJBPXRCY-UHFFFAOYSA-N 0.000 claims 3
- QHKABHOOEWYVLI-UHFFFAOYSA-N 3-methyl-2-oxobutanoic acid Chemical compound CC(C)C(=O)C(O)=O QHKABHOOEWYVLI-UHFFFAOYSA-N 0.000 claims 3
- 239000001142 4-methyl-2-oxopentanoic acid Substances 0.000 claims 3
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 3
- 235000021292 Docosatetraenoic acid Nutrition 0.000 claims 3
- 239000004471 Glycine Substances 0.000 claims 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 3
- HWXBTNAVRSUOJR-UHFFFAOYSA-N alpha-hydroxyglutaric acid Natural products OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 claims 3
- 229940009533 alpha-ketoglutaric acid Drugs 0.000 claims 3
- 229960003624 creatine Drugs 0.000 claims 3
- 239000006046 creatine Substances 0.000 claims 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 3
- 229960000310 isoleucine Drugs 0.000 claims 3
- 229940041290 mannose Drugs 0.000 claims 3
- 238000012544 monitoring process Methods 0.000 claims 3
- 229960002969 oleic acid Drugs 0.000 claims 3
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 229940055726 pantothenic acid Drugs 0.000 claims 3
- 235000019161 pantothenic acid Nutrition 0.000 claims 3
- 239000011713 pantothenic acid Substances 0.000 claims 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 3
- 235000014393 valine Nutrition 0.000 claims 3
- 239000004474 valine Substances 0.000 claims 3
- 229940075420 xanthine Drugs 0.000 claims 3
- 206010056997 Impaired fasting glucose Diseases 0.000 claims 2
- 229940122355 Insulin sensitizer Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 claims 1
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 claims 1
- 102000011690 Adiponectin Human genes 0.000 claims 1
- 108010076365 Adiponectin Proteins 0.000 claims 1
- YNXLOPYTAAFMTN-SBUIBGKBSA-N C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 YNXLOPYTAAFMTN-SBUIBGKBSA-N 0.000 claims 1
- 108010075254 C-Peptide Proteins 0.000 claims 1
- 108010023302 HDL Cholesterol Proteins 0.000 claims 1
- 102000001554 Hemoglobins Human genes 0.000 claims 1
- 108010054147 Hemoglobins Proteins 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 238000008214 LDL Cholesterol Methods 0.000 claims 1
- 108010028554 LDL Cholesterol Proteins 0.000 claims 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims 1
- 108010088847 Peptide YY Proteins 0.000 claims 1
- 102100029909 Peptide YY Human genes 0.000 claims 1
- 108010076181 Proinsulin Proteins 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 235000021588 free fatty acids Nutrition 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 235000020778 linoleic acid Nutrition 0.000 claims 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims 1
- 238000013178 mathematical model Methods 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 235000021313 oleic acid Nutrition 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000002769 thiazolinyl group Chemical group 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95028607P | 2007-07-17 | 2007-07-17 | |
| US60/950,286 | 2007-07-17 | ||
| US3762808P | 2008-03-18 | 2008-03-18 | |
| US61/037,628 | 2008-03-18 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010517019A Division JP5701601B2 (ja) | 2007-07-17 | 2008-07-17 | 糖尿病前症、心血管疾患及びその他のメタボリックシンドローム関連障害のバイオマーカー並びにその使用方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015236454A Division JP2016102797A (ja) | 2007-07-17 | 2015-12-03 | 糖尿病前症、心血管疾患及びその他のメタボリックシンドローム関連障害のバイオマーカー並びにその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015064362A JP2015064362A (ja) | 2015-04-09 |
| JP2015064362A5 true JP2015064362A5 (enExample) | 2015-05-28 |
| JP5876918B2 JP5876918B2 (ja) | 2016-03-02 |
Family
ID=40282019
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010517019A Active JP5701601B2 (ja) | 2007-07-17 | 2008-07-17 | 糖尿病前症、心血管疾患及びその他のメタボリックシンドローム関連障害のバイオマーカー並びにその使用方法 |
| JP2014218116A Active JP5876918B2 (ja) | 2007-07-17 | 2014-10-27 | 糖尿病前症、心血管疾患及びその他のメタボリックシンドローム関連障害のバイオマーカー並びにその使用方法 |
| JP2015236454A Pending JP2016102797A (ja) | 2007-07-17 | 2015-12-03 | 糖尿病前症、心血管疾患及びその他のメタボリックシンドローム関連障害のバイオマーカー並びにその使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010517019A Active JP5701601B2 (ja) | 2007-07-17 | 2008-07-17 | 糖尿病前症、心血管疾患及びその他のメタボリックシンドローム関連障害のバイオマーカー並びにその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015236454A Pending JP2016102797A (ja) | 2007-07-17 | 2015-12-03 | 糖尿病前症、心血管疾患及びその他のメタボリックシンドローム関連障害のバイオマーカー並びにその使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US8187830B2 (enExample) |
| EP (1) | EP2164977B1 (enExample) |
| JP (3) | JP5701601B2 (enExample) |
| AU (1) | AU2008279778B2 (enExample) |
| BR (1) | BRPI0815095B1 (enExample) |
| CA (1) | CA2690541A1 (enExample) |
| ES (1) | ES2443540T3 (enExample) |
| MX (3) | MX341954B (enExample) |
| WO (1) | WO2009014639A2 (enExample) |
Families Citing this family (127)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2008108B1 (en) * | 2006-03-24 | 2010-12-29 | Metanomics GmbH | MEANS AND METHOD FOR PREDICTING DIABETES type II |
| EP2053395A4 (en) * | 2006-08-04 | 2010-04-21 | Ajinomoto Kk | METABOLIC SYNDROME EVALUATION PROCEDURES, METABOLIC SYNDROME EVALUATION DEVICE, METABOLIC SYNDROME EVALUATION PROCEDURES, METABOLIC SYNDROME EVALUATION SYSTEM, METABOLIC SYNDROME EVALUATION PROGRAM AND RECORDING MEDIUM AND METHOD FOR SEARCHING FOR A PROPHYLACTIC / soothing SUBSTANCE FOR METABOLIC SYNDROME |
| US9867530B2 (en) | 2006-08-14 | 2018-01-16 | Volcano Corporation | Telescopic side port catheter device with imaging system and method for accessing side branch occlusions |
| EP2172775A4 (en) * | 2007-06-25 | 2010-12-01 | Ajinomoto Kk | METHOD OF EVALUATING VISCERAL GREASE ACCUMULATION |
| US9622706B2 (en) | 2007-07-12 | 2017-04-18 | Volcano Corporation | Catheter for in vivo imaging |
| US10219780B2 (en) | 2007-07-12 | 2019-03-05 | Volcano Corporation | OCT-IVUS catheter for concurrent luminal imaging |
| US9596993B2 (en) | 2007-07-12 | 2017-03-21 | Volcano Corporation | Automatic calibration systems and methods of use |
| JP5701601B2 (ja) * | 2007-07-17 | 2015-04-15 | メタボロン インコーポレイテッド | 糖尿病前症、心血管疾患及びその他のメタボリックシンドローム関連障害のバイオマーカー並びにその使用方法 |
| EP2209001A4 (en) * | 2007-10-25 | 2010-10-27 | Ajinomoto Kk | METHOD FOR ASSESSING STROKEN GLUCOSE TOLERANCE |
| EP2227689B1 (en) * | 2007-11-02 | 2012-12-26 | Metabolon, Inc. | Biomarkers for fatty liver disease and methods using the same |
| WO2009092068A1 (en) | 2008-01-18 | 2009-07-23 | President And Fellows Of Harvard College | Methods of detecting signatures of disease or conditions in bodily fluids |
| CN102066943A (zh) * | 2008-04-09 | 2011-05-18 | B.R.A.H.M.S有限公司 | 用于预测受损峰值耗氧量的内皮素1原 |
| US20100222315A1 (en) * | 2008-09-24 | 2010-09-02 | Harbor BioSciencs, Inc. | Patient populations and treatment methods |
| JP5393798B2 (ja) * | 2008-10-20 | 2014-01-22 | リポサイエンス，インコーポレイテッド | リポタンパク質インスリン抵抗性指数、ならびに同一物を生成するための関連する方法、システムおよびコンピュータプログラム |
| EP2405806A4 (en) | 2009-03-10 | 2014-01-22 | Univ Duke | PROGNOSIS OF CORONARY ARTERY DISEASE AND THE RISK OF CARDIOVASCULAR EVENTS |
| WO2010114897A1 (en) * | 2009-03-31 | 2010-10-07 | Metabolon, Inc. | Biomarkers related to insulin resistance and methods using the same |
| AU2010247750B2 (en) | 2009-05-11 | 2016-09-22 | Berg Llc | Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers |
| CN102625932A (zh) * | 2009-09-08 | 2012-08-01 | 诺达利蒂公司 | 细胞网络分析 |
| JP5787339B2 (ja) * | 2009-12-28 | 2015-09-30 | 学校法人福岡大学 | 糖尿病前症の検査方法 |
| CA2793735A1 (en) * | 2010-03-23 | 2011-09-29 | M. Daniel Raftery | Early detection of recurrent breast cancer using metabolite profiling |
| WO2011155518A1 (ja) | 2010-06-08 | 2011-12-15 | カルピス株式会社 | 脂質代謝改善剤 |
| MX361944B (es) | 2010-07-23 | 2018-12-19 | President And Fellows Of Harvard College Star | Metodos para detectar firmas de enfermedad o condiciones en fluidos corporales. |
| EP2596116A4 (en) | 2010-07-23 | 2014-03-19 | Harvard College | METHOD FOR DETECTING AUTOIMMUNE OR AUTOIMMUNE DISORDERS OR SUFFERING |
| CA2806304A1 (en) | 2010-07-23 | 2012-01-26 | President And Fellows Of Harvard College | Methods of detecting prenatal or pregnancy-related diseases or conditions |
| WO2012012709A2 (en) | 2010-07-23 | 2012-01-26 | President And Fellows Of Harvard College | Methods of detecting cardiovascular diseases or conditions |
| KR20130041962A (ko) | 2010-07-23 | 2013-04-25 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 식작용 세포를 사용하여 질환 또는 상태를 검출하는 방법 |
| US20130126725A1 (en) * | 2010-07-30 | 2013-05-23 | Technische Universität Graz | Analyses of Analytes by Mass Spectrometry with Values in at Least 3 Dimensions |
| WO2012058298A1 (en) * | 2010-10-26 | 2012-05-03 | Mayo Foundation For Medical Education And Research | Biomarkers of reduced insulin action |
| CN103403548A (zh) * | 2010-12-23 | 2013-11-20 | 梅坦诺米克斯保健有限公司 | 用于预测糖尿病的工具和方法 |
| US11141063B2 (en) | 2010-12-23 | 2021-10-12 | Philips Image Guided Therapy Corporation | Integrated system architectures and methods of use |
| US11040140B2 (en) | 2010-12-31 | 2021-06-22 | Philips Image Guided Therapy Corporation | Deep vein thrombosis therapeutic methods |
| WO2012116074A1 (en) * | 2011-02-22 | 2012-08-30 | Mayo Foundation For Medical Education And Research | Biomarkers of insulin sensitivity |
| KR101933732B1 (ko) | 2011-04-04 | 2018-12-28 | 버그 엘엘씨 | 중추 신경 시스템 종양들의 치료 방법 |
| JP6260275B2 (ja) | 2011-06-30 | 2018-01-17 | 味の素株式会社 | 脂肪肝の評価方法、脂肪肝評価装置、脂肪肝評価方法、脂肪肝評価プログラム、脂肪肝評価システム、および端末装置 |
| EP3527990A1 (en) * | 2011-07-28 | 2019-08-21 | metanomics GmbH | Use of sm_sphingomyelin (d18:1, c23:1) as a marker for heart failure |
| WO2013033592A1 (en) | 2011-08-31 | 2013-03-07 | Volcano Corporation | Optical-electrical rotary joint and methods of use |
| WO2013039898A1 (en) * | 2011-09-14 | 2013-03-21 | Metabolon, Inc. | Biomarkers related to insulin resistance and methods using the same |
| WO2013122469A2 (en) * | 2012-02-17 | 2013-08-22 | Rijksuniversiteit Groningen | Prediction of the efficacy of a medicament on renal or cardiovascular clinical outcomes |
| EP2642296A1 (en) * | 2012-03-22 | 2013-09-25 | Nestec S.A. | p-Cresol sulphate as biomarker for healthy ageing |
| EP2642293A1 (en) * | 2012-03-22 | 2013-09-25 | Nestec S.A. | 9-oxo-octadecadienoic acid (9-oxo-HODE)as as biomarker for healthy ageing |
| EP2642294A1 (en) * | 2012-03-22 | 2013-09-25 | Nestec S.A. | Phenylacetylglutamine as biomarker for healthy ageing |
| EP2642295A1 (en) | 2012-03-22 | 2013-09-25 | Nestec S.A. | 1-O-alkyl-2-acylglycerophosphocholine (PC-O) 40:1 as biomarker for healthy ageing |
| EP2642297A1 (en) * | 2012-03-22 | 2013-09-25 | Nestec S.A. | Hydroxy-sphingomyelin 22:1 as biomarker for healthy ageing |
| BR112014030243B1 (pt) * | 2012-06-05 | 2022-07-05 | Société Des Produits Nestlé S.A | Métodos para diagnosticar doença valvular crônica |
| US9361429B2 (en) | 2012-06-08 | 2016-06-07 | Liposcience, Inc. | Multi-parameter diabetes risk evaluations |
| US9928345B2 (en) | 2012-06-08 | 2018-03-27 | Liposciences, Inc. | Multiple-marker risk parameters predictive of conversion to diabetes |
| BR112014031414A2 (pt) | 2012-06-15 | 2017-06-27 | Stylli Harry | métodos de detectar doenças ou condições utilizando células doentes circulantes |
| SG11201408385TA (en) | 2012-06-15 | 2015-01-29 | Harry Stylli | Methods of detecting diseases or conditions |
| JP6282642B2 (ja) | 2012-06-27 | 2018-02-21 | メタノミクス ヘルス ゲーエムベーハー | 糖尿病薬を同定する方法 |
| EP2883058B1 (en) * | 2012-08-13 | 2018-01-03 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Biomarkers for type 2 diabetes |
| US20140324460A1 (en) * | 2012-09-26 | 2014-10-30 | Health Diagnostic Laboratory, Inc. | Method for determining and managing total cardiodiabetes risk |
| US9478940B2 (en) | 2012-10-05 | 2016-10-25 | Volcano Corporation | Systems and methods for amplifying light |
| US9307926B2 (en) | 2012-10-05 | 2016-04-12 | Volcano Corporation | Automatic stent detection |
| US9292918B2 (en) | 2012-10-05 | 2016-03-22 | Volcano Corporation | Methods and systems for transforming luminal images |
| US9367965B2 (en) | 2012-10-05 | 2016-06-14 | Volcano Corporation | Systems and methods for generating images of tissue |
| US9286673B2 (en) | 2012-10-05 | 2016-03-15 | Volcano Corporation | Systems for correcting distortions in a medical image and methods of use thereof |
| US10568586B2 (en) | 2012-10-05 | 2020-02-25 | Volcano Corporation | Systems for indicating parameters in an imaging data set and methods of use |
| US9858668B2 (en) | 2012-10-05 | 2018-01-02 | Volcano Corporation | Guidewire artifact removal in images |
| US11272845B2 (en) | 2012-10-05 | 2022-03-15 | Philips Image Guided Therapy Corporation | System and method for instant and automatic border detection |
| US10070827B2 (en) | 2012-10-05 | 2018-09-11 | Volcano Corporation | Automatic image playback |
| US9324141B2 (en) | 2012-10-05 | 2016-04-26 | Volcano Corporation | Removal of A-scan streaking artifact |
| US20140100454A1 (en) | 2012-10-05 | 2014-04-10 | Volcano Corporation | Methods and systems for establishing parameters for three-dimensional imaging |
| US9840734B2 (en) | 2012-10-22 | 2017-12-12 | Raindance Technologies, Inc. | Methods for analyzing DNA |
| JP6322210B2 (ja) | 2012-12-13 | 2018-05-09 | ボルケーノ コーポレイション | 標的化された挿管のためのデバイス、システム、および方法 |
| JP6785554B2 (ja) | 2012-12-20 | 2020-11-18 | ボルケーノ コーポレイション | 平滑遷移カテーテル |
| WO2014107287A1 (en) | 2012-12-20 | 2014-07-10 | Kemp Nathaniel J | Optical coherence tomography system that is reconfigurable between different imaging modes |
| US10939826B2 (en) | 2012-12-20 | 2021-03-09 | Philips Image Guided Therapy Corporation | Aspirating and removing biological material |
| JP2016506276A (ja) | 2012-12-20 | 2016-03-03 | ジェレミー スティガール， | 血管内画像の位置の特定 |
| US11406498B2 (en) | 2012-12-20 | 2022-08-09 | Philips Image Guided Therapy Corporation | Implant delivery system and implants |
| US10942022B2 (en) | 2012-12-20 | 2021-03-09 | Philips Image Guided Therapy Corporation | Manual calibration of imaging system |
| WO2014099763A1 (en) | 2012-12-21 | 2014-06-26 | Jason Spencer | System and method for graphical processing of medical data |
| EP2934280B1 (en) | 2012-12-21 | 2022-10-19 | Mai, Jerome | Ultrasound imaging with variable line density |
| US10420530B2 (en) | 2012-12-21 | 2019-09-24 | Volcano Corporation | System and method for multipath processing of image signals |
| EP2934653B1 (en) | 2012-12-21 | 2018-09-19 | Douglas Meyer | Rotational ultrasound imaging catheter with extended catheter body telescope |
| US9486143B2 (en) | 2012-12-21 | 2016-11-08 | Volcano Corporation | Intravascular forward imaging device |
| US9612105B2 (en) | 2012-12-21 | 2017-04-04 | Volcano Corporation | Polarization sensitive optical coherence tomography system |
| JP2016508233A (ja) | 2012-12-21 | 2016-03-17 | ナサニエル ジェイ． ケンプ， | 光学スイッチを用いた電力効率のよい光学バッファリング |
| US10058284B2 (en) | 2012-12-21 | 2018-08-28 | Volcano Corporation | Simultaneous imaging, monitoring, and therapy |
| WO2014100530A1 (en) | 2012-12-21 | 2014-06-26 | Whiseant Chester | System and method for catheter steering and operation |
| US9383263B2 (en) | 2012-12-21 | 2016-07-05 | Volcano Corporation | Systems and methods for narrowing a wavelength emission of light |
| ES2987582T3 (es) * | 2013-01-31 | 2024-11-15 | Metabolon Inc | Biomarcadores relacionados con la progresión de la resistencia a la Insulina y métodos que lo utilizan |
| WO2014118634A1 (en) * | 2013-01-31 | 2014-08-07 | Eustache Paramithiotis | Type 2 diabetes biomarkers and uses thereof |
| DE112014000822T5 (de) * | 2013-02-14 | 2015-10-29 | Metanomics Health Gmbh | Mittel und Verfahren zur Beurteilung der Qualität einer biologischen Probe |
| US10226597B2 (en) | 2013-03-07 | 2019-03-12 | Volcano Corporation | Guidewire with centering mechanism |
| CN113705586A (zh) | 2013-03-07 | 2021-11-26 | 飞利浦影像引导治疗公司 | 血管内图像中的多模态分割 |
| EP2965077B1 (en) | 2013-03-09 | 2022-07-13 | Harry Stylli | Methods of detecting cancer |
| US11585814B2 (en) | 2013-03-09 | 2023-02-21 | Immunis.Ai, Inc. | Methods of detecting prostate cancer |
| US11154313B2 (en) | 2013-03-12 | 2021-10-26 | The Volcano Corporation | Vibrating guidewire torquer and methods of use |
| EP2967391A4 (en) | 2013-03-12 | 2016-11-02 | Donna Collins | SYSTEMS AND METHOD FOR THE DIAGNOSIS OF CORONARY MICROVASCULAR DISEASES |
| US20140278121A1 (en) * | 2013-03-13 | 2014-09-18 | Robust for Life, Inc. | Systems and methods for network-based calculation and reporting of metabolic risk |
| US11026591B2 (en) | 2013-03-13 | 2021-06-08 | Philips Image Guided Therapy Corporation | Intravascular pressure sensor calibration |
| JP6339170B2 (ja) | 2013-03-13 | 2018-06-06 | ジンヒョン パーク | 回転式血管内超音波装置から画像を生成するためのシステム及び方法 |
| US9301687B2 (en) | 2013-03-13 | 2016-04-05 | Volcano Corporation | System and method for OCT depth calibration |
| CN105208947B (zh) | 2013-03-14 | 2018-10-12 | 火山公司 | 具有回声特性的过滤器 |
| US12343198B2 (en) | 2013-03-14 | 2025-07-01 | Philips Image Guided Therapy Corporation | Delivery catheter having imaging capabilities |
| US10292677B2 (en) | 2013-03-14 | 2019-05-21 | Volcano Corporation | Endoluminal filter having enhanced echogenic properties |
| US10219887B2 (en) | 2013-03-14 | 2019-03-05 | Volcano Corporation | Filters with echogenic characteristics |
| SG11201508272YA (en) | 2013-04-08 | 2015-11-27 | Berg Llc | Treatment of cancer using coenzyme q10 combination therapies |
| CA2921530A1 (en) | 2013-07-18 | 2015-01-22 | True Health Diagnostics, Llc | Method of determination of risk of 2 hour blood glucose equal to or greater than 140 mg/dl |
| HUE050060T2 (hu) | 2013-09-04 | 2020-11-30 | Berg Llc | Eljárások rák kezelésére koenzim Q10 folyamatos infúziójával |
| GB2524230A (en) * | 2014-02-14 | 2015-09-23 | Asda Stores Ltd | Transaction processing system and transaction processing method |
| US10626464B2 (en) | 2014-09-11 | 2020-04-21 | Cell Mdx, Llc | Methods of detecting prostate cancer |
| US20170316176A1 (en) * | 2014-12-25 | 2017-11-02 | Hitachi, Ltd. | Device for analyzing insulin secretion ability, system for analyzing insulin secretion ability provided with same, and method for analyzing insulin secretion ability |
| MX388989B (es) * | 2015-01-09 | 2025-03-11 | Global Genomics Group Llc | Biomarcadores basados en sangre para diagnosticar enfermedad de arteria coronaria ateroesclerótica. |
| US10451641B2 (en) | 2015-03-13 | 2019-10-22 | Duke University | Compositions and methods for metabolic profiling in subjects with heart failure with preserved ejection fraction |
| JP6051258B2 (ja) * | 2015-04-15 | 2016-12-27 | ライオン株式会社 | 脂質異常症への罹患しやすさを試験する方法 |
| KR101795689B1 (ko) * | 2015-04-30 | 2017-11-30 | 경희대학교 산학협력단 | 혈관 협착 질환 진단용 마커 및 이의 용도 |
| WO2017087576A1 (en) | 2015-11-16 | 2017-05-26 | Berg Llc | Methods of treatment of temozolomide-resistant glioma using coenzyme q10 |
| WO2018094204A1 (en) * | 2016-11-17 | 2018-05-24 | Arivale, Inc. | Determining relationships between risks for biological conditions and dynamic analytes |
| US11881311B1 (en) | 2017-02-17 | 2024-01-23 | BioAge Labs, Inc. | Survival prediction using metabolomic profiles |
| JP2018141728A (ja) * | 2017-02-28 | 2018-09-13 | トヨタ自動車株式会社 | 生活習慣病の診断方法 |
| AU2018371776A1 (en) * | 2017-11-22 | 2020-05-28 | Mayo Foundation For Medical Education And Research | Methods and materials for assessing and treating obesity |
| US20200041496A1 (en) * | 2018-08-01 | 2020-02-06 | Joshua Health Care LLC | Methods for Identifying and Treating Mammalian Subjects with Insulin Resistance |
| JP7189537B2 (ja) * | 2019-06-27 | 2022-12-14 | サンスター株式会社 | 血液試料の酸化ｈｄｌ量の反映値を測定する工程を含む、測定方法 |
| EP3997980A4 (en) * | 2019-07-08 | 2023-06-21 | Shimadzu Corporation | TRANSPLANT ORGAN FUNCTIONAL EVALUATION METHOD, TRANSPLANT ORGAN FUNCTIONAL EVALUATION PROGRAM AND TRANSPLANT ORGAN FUNCTIONAL EVALUATION DEVICE |
| US20240085432A1 (en) * | 2019-10-11 | 2024-03-14 | The Regents Of The University Of California | Metabolic profile screening for gestational diabetes |
| EP4100541A4 (en) * | 2020-02-05 | 2024-05-22 | The Cleveland Clinic Foundation | Disease detection and treatment based on phenylacetyl glutamine levels |
| CN113866284B (zh) * | 2020-06-30 | 2023-09-05 | 上海脉示生物技术有限公司 | 一组用于心力衰竭诊断的肠道微生物代谢标志物及其应用 |
| CN112684064B (zh) * | 2020-12-08 | 2022-05-17 | 安徽农业大学 | 用于筛选抗应激胁迫肉羊的血清代谢标志物及其应用 |
| WO2022133034A1 (en) * | 2020-12-16 | 2022-06-23 | St. Jude Children's Research Hospital, Inc. | Methods of treating disorders associated with castor |
| CN113325117B (zh) * | 2021-06-25 | 2022-07-15 | 中国医学科学院北京协和医院 | 一组生物标记物在制备预测静脉内平滑肌瘤病进展的试剂盒中的应用 |
| CN117741023A (zh) * | 2021-11-30 | 2024-03-22 | 江苏品生医疗科技集团有限公司 | 预测受试者患有糖尿病的可能性的标记物及其应用 |
| WO2023147522A1 (en) * | 2022-01-28 | 2023-08-03 | GATC Health Corp | Biomarkers for early detection of diabetes |
| CN114965733B (zh) * | 2022-04-07 | 2023-12-01 | 中国人民解放军总医院第一医学中心 | 结直肠进展期腺瘤诊断代谢标志物组合及其应用 |
| WO2025019706A1 (en) * | 2023-07-19 | 2025-01-23 | Ahara Corporation | Systems and methods for generating a nutrition program |
| JP2025112741A (ja) * | 2024-01-22 | 2025-08-01 | 富士フイルム株式会社 | 情報管理装置及び情報管理装置の作動方法並びに情報管理プログラム |
| CN119846232B (zh) * | 2025-01-21 | 2025-10-03 | 宁夏农林科学院动物科学研究所(宁夏草畜工程技术研究中心) | 一种早期诊断奶牛隐性乳房炎的生物标志物组合及其应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5367052A (en) * | 1987-04-27 | 1994-11-22 | Amylin Pharmaceuticals, Inc. | Amylin peptides |
| EP0825258A4 (en) * | 1996-02-20 | 2001-12-05 | Kyowa Hakko Kogyo Kk | METHOD OF DETERMINING 1,5-ANHYDROGLUCITOL |
| JP2938048B1 (ja) * | 1998-06-30 | 1999-08-23 | 技術研究組合医療福祉機器研究所 | 代謝機能測定装置 |
| US6140067A (en) * | 1999-04-30 | 2000-10-31 | Mitokor | Indicators of altered mitochondrial function in predictive methods for determining risk of type 2 diabetes mellitus |
| JP3975279B2 (ja) * | 1999-11-01 | 2007-09-12 | 旭化成ファーマ株式会社 | 糖尿病予備群の検査方法 |
| US7329489B2 (en) * | 2000-04-14 | 2008-02-12 | Matabolon, Inc. | Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| US20020009740A1 (en) * | 2000-04-14 | 2002-01-24 | Rima Kaddurah-Daouk | Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| PL365135A1 (en) * | 2000-08-07 | 2004-12-27 | Ranbaxy Signature Llc | Liquid formulation of metformin |
| CN1533435A (zh) * | 2001-06-01 | 2004-09-29 | 克林杰尼克斯公司 | 用于诊断及治疗胰岛素抗性及相关病症之方法和试剂 |
| US7425545B2 (en) * | 2001-07-25 | 2008-09-16 | Isis Pharmaceuticals, Inc. | Modulation of C-reactive protein expression |
| JP4100673B2 (ja) * | 2001-12-07 | 2008-06-11 | 日本化薬株式会社 | 肝糖放出の検査方法 |
| JP2003204800A (ja) * | 2002-01-15 | 2003-07-22 | Sumitomo Pharmaceut Co Ltd | 糖代謝異常疾患マーカーおよびその利用 |
| US20040101874A1 (en) * | 2002-04-12 | 2004-05-27 | Mitokor Inc. | Targets for therapeutic intervention identified in the mitochondrial proteome |
| AU2003246644A1 (en) * | 2002-07-08 | 2004-01-23 | Genova, Ltd. | Secreted peptides |
| JP2005006645A (ja) * | 2003-05-22 | 2005-01-13 | Sumitomo Chemical Co Ltd | インスリン応答性の評価方法 |
| US7648825B2 (en) * | 2003-06-20 | 2010-01-19 | University Of Florida Research Foundation, Inc. | Biomarkers for differentiating between type 1 and type 2 diabetes |
| US7345142B2 (en) * | 2004-01-27 | 2008-03-18 | Compugen Ltd. | Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of cardiac disease |
| JP4547173B2 (ja) * | 2004-03-17 | 2010-09-22 | シスメックス株式会社 | 糖尿病診療支援システム |
| JP4533042B2 (ja) * | 2004-08-25 | 2010-08-25 | 裕 笹川 | 糖尿病および糖代謝異常を判断する方法 |
| US20080261317A1 (en) * | 2004-09-07 | 2008-10-23 | Fifer Michael A | Methods of Detecting Myocardial Ischemia and Myocardial Infarction |
| JP4522222B2 (ja) * | 2004-10-22 | 2010-08-11 | 扶桑薬品工業株式会社 | 血中脂肪酸濃度測定による心疾患の早期診断方法 |
| WO2006063733A1 (en) * | 2004-12-14 | 2006-06-22 | F.Hoffmann-La Roche Ag | Cd99 as target/marker for insulin resistance |
| US20070026458A1 (en) * | 2004-12-17 | 2007-02-01 | Entelos, Inc. | Assessing insulin resistance using biomarkers |
| WO2006073195A1 (ja) * | 2005-01-07 | 2006-07-13 | Biomarker Science Co., Ltd | 糖尿病の予知・診断方法および糖尿病予知・診断用キット |
| FR2890079B1 (fr) * | 2005-08-26 | 2007-11-30 | Alain Rambach | Detection des salmonelles lactose + |
| WO2007038670A2 (en) * | 2005-09-30 | 2007-04-05 | Perlegen Sciences, Inc. | Methods and compositions for screening and treatment of disorders of blood glucose regulation |
| US20070218519A1 (en) * | 2005-10-11 | 2007-09-20 | Tethys Bioscience, Inc. | Diabetes-associated markers and methods of use thereof |
| JP2007127423A (ja) * | 2005-10-31 | 2007-05-24 | Toray Ind Inc | ３−ヒドロキシ酪酸の測定方法およびキット |
| EP2008108B1 (en) * | 2006-03-24 | 2010-12-29 | Metanomics GmbH | MEANS AND METHOD FOR PREDICTING DIABETES type II |
| WO2008118413A2 (en) * | 2007-03-26 | 2008-10-02 | Bg Medicine, Inc. | Methods for detecting coronary artery disease |
| JP5701601B2 (ja) * | 2007-07-17 | 2015-04-15 | メタボロン インコーポレイテッド | 糖尿病前症、心血管疾患及びその他のメタボリックシンドローム関連障害のバイオマーカー並びにその使用方法 |
| WO2010114897A1 (en) * | 2009-03-31 | 2010-10-07 | Metabolon, Inc. | Biomarkers related to insulin resistance and methods using the same |
| CN103403548A (zh) * | 2010-12-23 | 2013-11-20 | 梅坦诺米克斯保健有限公司 | 用于预测糖尿病的工具和方法 |
-
2008
- 2008-07-17 JP JP2010517019A patent/JP5701601B2/ja active Active
- 2008-07-17 MX MX2013008169A patent/MX341954B/es unknown
- 2008-07-17 EP EP08780229.4A patent/EP2164977B1/en active Active
- 2008-07-17 MX MX2016009020A patent/MX377928B/es unknown
- 2008-07-17 WO PCT/US2008/008756 patent/WO2009014639A2/en not_active Ceased
- 2008-07-17 MX MX2010000414A patent/MX2010000414A/es active IP Right Grant
- 2008-07-17 US US12/218,980 patent/US8187830B2/en active Active
- 2008-07-17 AU AU2008279778A patent/AU2008279778B2/en active Active
- 2008-07-17 BR BRPI0815095-8A patent/BRPI0815095B1/pt active IP Right Grant
- 2008-07-17 ES ES08780229.4T patent/ES2443540T3/es active Active
- 2008-07-17 CA CA2690541A patent/CA2690541A1/en not_active Abandoned
-
2012
- 2012-04-27 US US13/457,620 patent/US8546098B2/en active Active
-
2013
- 2013-08-14 US US13/966,475 patent/US8809008B2/en active Active
-
2014
- 2014-07-07 US US14/324,689 patent/US9250225B2/en active Active
- 2014-10-27 JP JP2014218116A patent/JP5876918B2/ja active Active
-
2015
- 2015-12-03 JP JP2015236454A patent/JP2016102797A/ja active Pending
- 2015-12-21 US US14/975,988 patent/US10175233B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015064362A5 (enExample) | ||
| JP2012522989A5 (enExample) | ||
| JP2010537157A5 (enExample) | ||
| HK1199754A1 (en) | Method for monitoring, diagnosis and/or prognosis of acute kidney injury in early stage | |
| EP3865135A3 (en) | Neuroactive steroids for use in therapy | |
| EP4335931A3 (en) | Therapeutic and diagnostic methods for cancer | |
| WO2015094995A3 (en) | Gene signature biomarkers of tumor response to pd-1 antagonists | |
| EA201391017A1 (ru) | Способы и готовые лекарственные формы для лечения болезни альцгеймера | |
| WO2014036495A3 (en) | Diagnostic assays and kits for detection of folate receptor 1 | |
| HK1250752A1 (zh) | 治疗骨髓增生性障碍的方法 | |
| WO2009090553A3 (en) | Compositions and methods of detecting post-stop peptides | |
| JP7123329B2 (ja) | 腎臓病の予後予測方法及びシステム | |
| MX2017003370A (es) | Composiciones, metodos y kits para el diagnostico de una neoplasia neuroendocrina gastroenteropancreatica. | |
| WO2015094996A3 (en) | Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists | |
| JP2015530877A5 (enExample) | ||
| WO2015057968A3 (en) | Methods of identifying subjects responsive to treatment for an autoimmune disease and compositions for treating the same | |
| WO2012032345A3 (en) | Biomarker signatures and uses thereof | |
| WO2015049390A3 (en) | Kidney disease biomarker | |
| JP2014505254A5 (enExample) | ||
| WO2015048804A3 (en) | Protein biomarker and uses thereof | |
| WO2018026969A3 (en) | Plazomicin antibodies and methods of use | |
| WO2006084299A3 (en) | Method for evaluating the allergen sensitivity of an individual | |
| HK1258207A1 (zh) | 基於鉴别和改善肝功能障碍来诊断和治疗帕金森病 | |
| BR112013030646A2 (pt) | uso diagnóstico de pró-somatostatina | |
| HK1258760A1 (zh) | 血肌酐和免疫抑制药物的检测方法 |